The National Commission into the Regulation of AI in Healthcare published its recommendations on September 10, 2026, calling on the Medicines and Healthcare products Regulatory Agency to treat new medical AI more like a learner driver than a finished device. The independent panel, set up by the MHRA in September 2025 and chaired by NHS doctors Professor Alastair Denniston and Professor Henrietta Hughes, wants staged authorisations, continuous real-world monitoring, a public safety database, and tougher enforcement powers.

The GOV.UK notice says the Commission took evidence from more than 12,000 patients, clinicians, health leaders, and developers, which it called the largest UK engagement of its kind on healthcare technology. The Health Foundation ran extra deliberative research with the public, published the same day. The finding the Commission leaned on is simple: people will accept AI in care if safety standards are high, a human stays in the loop, and they are told when a model is being used.

Staged authorisation would let a new model ship under close supervision and tight guardrails, then earn a fuller license after it shows real-world performance. That is meant to get UK patients earlier access without a single yes-or-no decision at launch. The panel also said AI devices should be watched for their whole working life, because the software keeps changing after the approval letter, and that the public should be able to search safety records the way they can already search MHRA drug analysis profiles.

Lawrence Tallon, the MHRA’s chief executive, welcomed the report and said a modern framework has to accelerate safe adoption and still command public trust. The government and the MHRA will consider the recommendations and publish a formal response later. The notice notes that the NHS already uses AI to flag strokes and skin cancers and to cut admin with voice tools. The Commission included contributors from the United States and Singapore.

Decoded Take

Britain has spent two years talking about being the best place to build health AI. This report is the first time a doctor-led panel has said, in public, that the approval process itself is the bottleneck and sketched a learner-plate alternative. Staged authorisation only works if the second stage can fail. If the MHRA treats the L-plate as a courtesy ramp into full clearance, patients get earlier exposure without earlier accountability. The 12,000-person consultation gives ministers cover to claim a mandate. The tell is the formal response: whether staged licences, a searchable incident file, and new enforcement powers show up as draft rules, or whether this lands as another white paper. Watch the MHRA response date, the first model that ships under a restricted authorisation, and whether a public incident record is live before that model is used on a ward.